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ABSTRACT  
Objective: To assess the efficacy of golimumab (GLM) in refractory uveitis associated 
to spondyloarthritis (SpA). 
Methods: Multicenter study of SpA-related uveitis refractory to at least one 
immunosuppressive drug. The main outcome variables were degree of anterior and 
posterior chamber inflammation, visual acuity, and macular thickness. 
Results: Fifteen patients (13 men/2 women; 18 affected eyes; mean age 39±6 years) 
were evaluated. The underlying SpA subtypes were ankylosing spondylitis (n=8), 
psoriatic arthritis (n=6) and non-radiographic axial SpA (n=1). The ocular involvement 
patterns were recurrent anterior uveitis in 8 patients and chronic anterior uveitis in 7. 
Before GLM they have received methotrexate (n=13), sulfasalazine (n=6), pulses of 
methylprednisolone (n=4), azathioprine (n=3), leflunomide (n=2) and cyclosporine 
(n=1). Ten of them had also been treated with TNF-α blockers; etanercept (n=7), 
adalimumab (n=7), infliximab (n=6), and certolizumab (n=1). GLM was given at the 
standard dose (50 mg/sc/monthly) as monotherapy (n=7) or in combination with 
conventional immunosuppressive drugs (n=8), mainly methotrexate. Most patients had 
rapid and progressive improvement of intraocular inflammation parameters. The 
median number of cells in the anterior chamber at 2 years (0 [0-0]) was significantly 
reduced compared to baseline findings (1 [0-3]); p=0.04). The mean best corrected 
visual acuity value also improved (0.84±0.3 at 2 years versus 0.62±0.3 at baseline; 
p=0.03). Only minor side effects were observed after a mean follow-up of 23±7 months.  
Conclusions: Our results indicate that GLM may be a useful therapeutic option in 







The term spondyloarthritis (SpA) encompasses a group of chronic inflammatory 
diseases characterized by joint involvement and extra-articular manifestations strongly 
associated with HLA B27 antigen (1-4). It includes reactive arthritis (formerly called 
Reiter syndrome), ankylosing spondylitis (AS), inflammatory bowel disease (Crohn‟s 
disease and ulcerative colitis), undifferentiated SpA and psoriatic arthritis (PsA) (1-4).  
Uveitis, the most common extra-articular manifestation of SpA (5,6), has been included 
in the recently proposed classification criteria for axial and peripheral SpA (7,8). The 
most frequent pattern of ocular involvement in SpA is a recurrent acute unilateral 
anterior uveitis, which usually resolves with topical therapy (9,10). In some cases, 
however, uveitis may be refractory or relapsing, and treatment with an additional 
conventional immunosuppressive agents (mainly sulfasalazine or methotrexate) may 
be required (9,11-13). 
Despite using topical and conventional immunosuppressive agents, uveitis sometimes 
becomes chronic or relapsing leading to major ocular sequelae. According to published 
data, up to one-third of patients experience substantial visual impairment and up to 
10% become blind (9,10,14,15). Based on the recent Expert Panel Recommendations, 
infliximab (IFX) or adalimumab (ADA) are used when SpA-related severe, visual 
threatening or debilitating uveitis occurs (9). These recommendations are based on 
several studies showing the efficacy of anti-tumor necrosis factor-alpha (anti-TNF-α) 
agents in uveitis associated with SpA (16-19). With respect to this, monoclonal 
antibodies seem to be more effective than the soluble receptor etanercept in most 
cases of uveitis (20) including SpA-related uveitis (21). 
Although IFX or ADA are the first-line recommended monoclonal antibodies for the 
management of SpA-uveitis refractory to conventional drugs, in some cases 
inadequate response, due to either intolerance or inefficacy, may be observed following 
the use of these two biologic agents. These patients represent a major challenge for 
the clinician, since no well-establish approach has been suggested to deal with these 
cases. To provide an alternative therapeutic option in refractory SpA-related uveitis, we 
have used Golimumab (GLM), a novel fully humanized anti-TNF-α monoclonal antibody 
that has been approved for the treatment of rheumatoid arthritis, PsA, AS and 
ulcerative colitis (22-24). Compared to IFX, GLM is administered by subcutaneous 
route and has a lower risk for developing neutralizing antibodies. Moreover, it has 
potential advantages over ADA, as its monthly administration. However, the few 
published studies on the efficacy of GLM in refractory uveitis are based on small case 
series (25) or heterogeneous subgroups of patients with this disorder (26-32). 
Taking into account all these considerations, we conducted a multicenter study to 
analyze the clinical response to GLM in patients diagnosed with SpA-related uveitis 
refractory to other systemic immunosuppressive agents. 
 
2. PATIENTS AND METHODS 
This is an open-label, multicenter study including 15 patients with SpA-related uveitis. 
All of them had been refractory to previous standard synthetic immunosuppressive 
drugs and in some cases to at least one anti-TNF-α agent. 
 
2.1. Working definitions 
SpA was diagnosed according to the proposed classification criteria for axial or 
peripheral SpA (8). The diagnosis of AS was made following the modified New York 
criteria (33) and that of PsA according to the Classification criteria for Psoriatic Arthritis 
(CASPAR) (34). 
Refractory uveitis was defined when the patient did not achieve clinical remission 
despite of the use of standard synthetic immunosuppressive drugs and/or anti-TNF-α 
agents or whether the treatment with these drugs was not sufficient to reach disease 
remission (26, 35-37).  
Uveitis was classified anatomically, according to the International Uveitis Study Group 
(IUSG) classification (38). The degree of intraocular inflammation was evaluated 
according to "The Standardization of Uveitis Nomenclature (SUN) Working Group" 
(39). Nussenblat scale was used to evaluate the degree of vitritis (40). Macular 
thickness was measured by optical coherence tomography (OCT). Macular thickening 
was defined as a macular thickness greater than 250 μm whereas cystoid macular 
edema (CME) was defined as a macular thickness greater than 300 μm. The best-
corrected visual acuity (BCVA) was determined using the Snellen test.  
 
2.2. GLM protocol 
GLM was given subcutaneously at the dose of 50 mg monthly. Before GLM onset, 
evidence of malignancy or systemic infection, including hepatitis B or hepatitis C 
infection, were excluded. According to the Spanish National Guidelines, in all patients 
receiving anti-TNF-α drugs, latent tuberculosis was excluded by a tuberculin skin 
testing (PPD) and/or quantiferon and chest radiograph. Patients with latent tuberculosis 
received prophylaxis with isoniazid at least 4 weeks before the onset of the biologic 
agent. Overall, prophylaxis was maintained for 9 months. Since GLM is an off-label 
indication for uveitis, written informed consent was obtained from all the patients.  
 
2.3. Statistical analysis 
Clinical and laboratory variables were collected by each investigator following a 
protocol agreed beforehand. Categorical variables were expressed as percentages. 
Continuous variables were expressed as mean±SD or as median [25th-75th 
interquartile range (IQR)] as appropriate, and compared by using the Wilcoxon signed-
rank test. Snellen visual acuities were converted to logarithm of the minimum angle of 
resolution (logMAR) scores for statistical analysis.  
Intraocular inflammation, macular thickness, BCVA, and sparing corticosteroid effect 
were the outcome variables. These variables were recorded in most patients at 
baseline and at 1 week, 2 weeks, 1 month, 3 months, 6 months and 1 and 2 years.  
Statistical analysis was performed using the STATISTICA software (StatSoft Inc. Tulsa, 
Oklahoma, USA). 
 
3. RESULTS  
3.1. Baseline features 
Fifteen patients (18 affected eyes) with SpA-related uveitis who were treated with GLM 
were assessed. The main baseline characteristics of this series of patients are 
summarized in the Table 1. As expected, most patients were young men (n=13; 
86.7%; mean age 39±6 years; median (range) age 39 (31- 48) years, and HLA-B27 
was positive in 11 cases. The most frequent underlying SpA subtype was AS (n=8) 
followed by PsA (n=6) and non-radiographic axial SpA (n=1). 
The most common synthetic therapy given before GLM were methotrexate (n= 13) and 
sulfasalazine (n=6). Four patients had received pulses of methylprednisolone. Other 
drugs given before GLM onset were azathioprine (n=3), leflunomide (n=2), 
cyclosporine (n=1). It is worth noting that 10 of these 15 patients had also been treated 
with TNF-α blockers; etanercept (n=7), adalimumab (n=7), infliximab (n=6), and 
certolizumab (n=1). The drugs given to each patient before the onset of GLM therapy 
are shown in Table 1.  
Uveitis had been relapsing in 8 cases and chronic the other 7 cases. At GLM onset, all 
the patients showed active uveitis with cells in anterior chamber. Vitritis was seen in 4 
cases, and CME and retinal vasculitis in 3 and 1 patient, respectively. In addition, at the 
time of GLM onset some patients already had visual sequelae: cataracts (n=3), 
cataracts and persistent CME (n=1), synechiae (n=5) and glaucoma (n=4). Besides 





3.2. GLM therapeutic scheme 
Figure 1 shows the flow chart showing all the biologic agents received by the patients 
included in this study. GLM was used as monotherapy in 7 cases and in combination 
with conventional immunosuppressive drugs in the remaining 8 patients (MTX in 5, 
LFN in 2, and AZA in 1 case). As described before, the standard GLM regimen was 50 
mg/sc every 4 weeks. However, the dose had to be increased to 100 mg/sc every 4 
weeks in 1patient due to a new outbreak of uveitis after 4 months of GLM therapy. 
 
3.3. Outcome variables 
Macular thickness and BCVA showed a rapid and maintained improvement (Figures 
2A, 2B) after GLM therapy. Thus, the mean BCVA increased from 0.62±0.3 before 
GLM onset to 0.84±0.3 after 2 years of treatment (p=0.03). 
Most patients had rapid and progressive improvement of intraocular inflammation 
parameters (anterior chamber cells, vitritis and OCT >250 μm) (Figures 3A, 3B and 
3C). In this regard, a reduction of anterior chamber cells from a median [IQR] of 1 [0-3] 
at baseline to 0 [0-0] at 2 years of treatment with GLM, was observed (p=0.04).  
Moreover, OCT values improved from 295±42.2 μm at GLM onset to 259.2±10.3 μm 
after 2 years of treatment, although this difference was not statistically significant 
(p=0.36). 
 
3.4. Other clinical findings and side-effects following GLM therapy 
We have also observed a decrease, albeit non-significant, in the frequency of uveitis 
outbreaks that fell from 5 [3-6] outbreaks/year before GLM onset to 0.5 [0-3.5] 
outbreaks/year following GLM therapy (p=0.08). 
Interestingly, a corticosteroid sparing effect was also observed at 2 years (Figure 4). 
Thus, the mean daily dose of prednisone was reduced from 34.4±19.4 mg at baseline 
to 9.2±7.3 mg at 2 years (p=0.04). 
After a median follow-up of 23±7 months, 13 patients achieved complete clinical 
remission. In one case, in which remission was not achieved after 26 months of 
treatment with GLM, this agent was withdrawn, and ADA was started with good 
response after 14 months of therapy. In another patient, who was in clinical remission, 
GLM was discontinued after 36 months of treatment because he was diagnosed with a 
renal adenocarcinoma. He was switched to 20 mg/day remaining asymptomatic of the 
uveitis since them. 
Regarding the safety profile of GLM, we have observed a local injection-site reaction in 
1 case, a mild facial herpes zoster which evolved favorably with oral antiviral therapy 
and the above mentioned case of renal adenocarcinoma. 
 
4. DISCUSSION 
Herein, we report on 15 patients with SpA-related uveitis refractory to synthetic 
conventional immunosuppressive drugs, 10 of them also refractory to anti-TNF-α 
agents. Most of them achieved response to GLM therapy.  
Uveitis prevalence in SpA ranges from 10 to 50% depending on the selected study (6, 
41), the subtype of SpA (it is higher in AS and lower in undifferentiated SpA) (6), and 
HLA-B27 positivity (ranging between 40- 48% in HLA-B27 positive and 15-25% in HLA-
B27 negative patients). (42-44). 
The typical pattern in SpA-related uveitis is a unilateral, recurrent, and acute anterior 
involvement (45). However, there are differences in the ocular pattern depending on 
the subtype of SpA. Thus, uveitis in AS is usually acute, unilateral and of sudden onset. 
In contrast, uveitis in PsA tends to be chronic, bilateral and with insidious onset (46-
49). 
The prognosis of anterior uveitis is favourable in most patients. However, in some 
cases, especially in HLA-B27-postive patients, uveitis has less favourable outcome, 
and fibrin deposits in the anterior chamber, hypopyon, recurrences and sequelae, 
including CME, papillitis, cataracts, glaucoma, synechiae and severe vitritis, may be 
seen, leading to legal blindness or severe visual impairment in 10% of the patients 
(14,15,50-52). 
Concerning to therapy, SpA-related anterior uveitis is usually treated successfully with 
topical therapy that includes corticosteroids and often a dilating drop to prevent 
posterior synechiae and to reduce spasm of the ciliary muscle. Severe unilateral 
disease with a sudden onset may require locally injected corticosteroids or a brief 
course of oral prednisone. When uveitis is bilateral, relapsing or more severe, 
additional immunosuppressive therapy, mainly sulfasalazine and MTX, may be needed 
to achieve adequate control the disease (9, 11-13, 46).  
In some patients, uveitis is refractory to these synthetic drugs, and some evidence 
suggests that anti-TNF-α monoclonal antibodies are more effective than the TNF 
soluble receptor (etanercept) for the treatment and prevention of uveitis (20, 21). 
Paradoxically, in some cases TNF-α inhibitors, mainly etanercept, have been reported 
to cause uveitis (53, 54). 
According to the Expert Panel Recommendations, IFX or ADA are the first line 
monoclonal anti-TNF-α drugs recommended to treat refractory SpA-related uveitis (9). 
There are a number of studies now to prove the efficacy of these anti-TNF-α 
monoclonal antibodies in uveitis (35, 37, 55-57). This approach is based on the finding 
of high TNF-α level in the aqueous humor (58) and the inflamed joints (59) of patients 
with SpA. These biologic agents have shown to improve not only the musculoskeletal 
symptoms of SpA (60, 61) but also to prevent new outbreaks of SpA-related uveitis and 
to control chronic uveitis in most cases (16, 18).  
Regrettably, a problem arises when refractory SpA-related uveitis has inadequate 
response to ADA or IFX therapy. In these cases, there is no well- established 
therapeutic protocol to be followed. Certolizumab has been suggested to be an 
effective agent to reduce frequency of SpA-related uveitis relapses, although data are 
scarce yet (62). On the other hand, GLM is a novel fully humanized anti-TNF-α 
monoclonal antibody approved to treat rheumatoid arthritis, PsA, AS and ulcerative 
colitis (22, 23, 63-65). GLM has been reported to be as a safe agent in these conditions 
with a side-effect profile similar to other commercially available anti-TNF-α drugs (22, 
66). Compared with the most commonly used anti-TNFα drugs, GLM has advantages 
in the route and periodicity of administration. Moreover, GLM is a fully human 
monoclonal antibody. This fact may potentially reduce the risk to develop neutralizing 
antibodies and allergic reactions (29-32). 
There are several reports that highlight the effectiveness of GLM in immune-mediated 
uveitis. However, information on the efficacy of GLM in refractory SpA-related uveitis is 
scarce (8, 27-32). Our results indicate that GLM may be an effective therapy for SpA-
related uveitis refractory to immunosuppressive drugs, also including in some cases 
other anti-TNF-α biologic agents. Moreover, besides its efficacy to maintain intraocular 
inflammation remission, our results suggest that GLM may be useful to prevent further 
relapses in SpA patients with recurrent episodes of uveitis. In this regard, our data are 
in keeping with the scarce published results reported in heterogeneous groups of 
patients with uveitis that only included a few patients with SpA (26, 27, 29). Moreover, 
our multicenter open-label study represents the largest series published on refractory 
SpA-related uveitis. 
With respect to adverse side effects, although in our study we observed a case of renal 
carcinoma, there are many studies showing that there is no increased risk of tumors in 
patients treated with anti-TNF-α drugs. Therefore, it is possible that the occurrence of 
renal cancer in this case might have been an incidental finding unrelated to GLM  (67). 
 
5. CONCLUSION 
In conclusion, our results indicate that GLM may be a useful therapeutic option in 
refractory SpA-related uveitis. 
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TABLE 1. Main epidemiological, underlying spondyloarthritis (SpA), treatment and 
ophthalmologic features of a series of 15 patients with SpA undergoing golimumab 






















1 37 Man + AS 
AU/ chronic/ 
unilateral 






2 32 Man + AS 
AU/ chronic/ 
bilateral 






3 45 Man + AS 
AU/recurrent
/ unilateral 

























































































































































AC cells MTX uveitis 
Abbreviations: AS=ankylosing spondylitis; nr-axSpA=non radiographic axial spondyloarthritis; PsA=psoriatic 
arthritis; AU= anterior uveítis; AC cells=anterior  chamber cells; CME= cystoid macular edema; 
MTX=methotrexate; SSZ=salazopyrin; IFX=infliximab; ADA=adalimumab; ETN= etanercept; 
AZA=azathioprine; CZP=certolizumab; LFN=leflunomide; CsA=cyclosporine 
FIGURE 1.  Flow-chart of 15 patients with refractory uveitis related to spondyloarthritis 












Abbreviations:   IFX=infliximab; ADA= adalimumab; ETN= etanercept; CZP= certolizumab; 
GLM= golimumab 
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FIGURE 2.  Rapid and maintained improvement following the onset of GLM therapy 
(data expressed as mean values compared with basal results): (A) macular thickness 
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FIGURE 3.  Golimumab therapy led to improvement of active inflammation of: (A) 
Anterior chamber cells (AC cells), (B) vitritis and (C) OCT values. Data were expressed 
when any score of activity was present as percentage of affected eyes. Active 
inflammation was considered if: AC cells > 0, vitritis > 0 and optical coherence 
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FIGURE 4.  Sparing corticosteroid-sparing effect following GLM therapy in a series of 
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